Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nipocalimab in adults with active systemic lupus erythematosus
jRCT2041210058Recruiting
- Sponsor
- Janssen Pharmaceutical
- Start
- Feb 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
01
Overview
Randomised, double-blind trial of nipocalimab in systemic lupus erythematosus (SLE) (3 arms), sponsored by Janssen Pharmaceutical. Primary endpoint: Percentage of participants achieving SLE Responder Index-4 composite response at Week 24. Started Feb 2022; status: recruiting.
02
Drugs
nipocalimab
03
Conditions
systemic lupus erythematosus (SLE)
Beyond the preview
Go deeper on jRCT2041210058.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2041210058.